Remove Bacteria Remove Containment Remove Trials
article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. percentage points (96% CI, −0.3

article thumbnail

Is the microbiome therapy hype up for a reckoning?

Pharmaceutical Technology

Finch Therapeutics’s Phase III PRISM4 trial for recurrent Clostridioides difficile infection (CDI) and MaaT Pharma’s Phase III trial in steroid-resistant acute graft-versus-host disease were both put on hold. While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. with placebo.

Bacteria 278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

Additionally, it will work on non-clinical toxicity (TOX) and Clinical Trial Material batch to conduct a Phase I clinical trial of the vaccine in healthy adult subjects. This trial will evaluate the safety of the vaccine and generate efficacy data. A sexually transmitted disease, gonorrhoea is caused by the NG bacteria.

article thumbnail

Engineering an “invisible cloak” for bacteria to deliver drugs to tumors

The Pharma Data

Columbia Engineering researchers report that they have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. Using Bacteria For Therapy. Some trials had to be terminated due to severe toxicity.”

article thumbnail

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Pfizer

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

article thumbnail

Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial

Delveinsight

Remarkable drop was observed in altered filamin A plasma levels after treatment with simufilam in Phase 2b trials. a biotechnology (clinical stage immuno-oncology) company from California publicized the design of its new XPro therapy in Phase 2 clinical trials. P-tau 181 plasma levels were also reduced in a good amount. gingivalis.

article thumbnail

International Day of Epidemic Preparedness 2024: Amplifying Global Resilience

XTalks

The WHO contained a Marburg virus outbreak in Tanzania in early 2024 with nine cases and six deaths. Universal vaccines, such as a pan-coronavirus candidate in late-stage trials, aim to provide cross-protection against multiple strains. Global travel further accelerates disease spread, complicating containment efforts.